Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional information from Jingze Biotech regarding its recent shareholder changes and other compliance matters as part of its application for listing on the Hong Kong Stock Exchange [1][2]. Group 1: Regulatory Requirements - CSRC requires Jingze Biotech to explain the reasons for new shareholders joining in the last 12 months and the rationale behind the share prices, including any discrepancies and potential issues of abnormal pricing or benefit transfer [1]. - The company must clarify the progress of state-owned shareholders in handling state-owned stock identification [1]. - Jingze Biotech is asked to confirm whether its business scope, particularly in "cell technology research and application" and "developing candidate drugs that regulate pathogenic genes at the DNA or RNA level," involves any foreign investment restrictions or prohibited areas [1]. - The company needs to provide details on its previous A-share listing guidance and whether it plans to continue pursuing A-share listing, including any significant impacts on the current listing process [1]. Group 2: Company Overview - Jingze Biotech is a biopharmaceutical company focused on high-growth sectors of assisted reproductive drugs and ophthalmic drugs, addressing unmet clinical needs [2]. - The company has established a comprehensive R&D system and commercial-scale production capabilities, having developed multiple product pipelines with high technical barriers and significant commercial potential, advancing several drugs to late-stage clinical and commercialization phases [2].
新股消息 | 景泽生物拟港股上市 中国证监会要求补充说明最近12个月内新增股东入股原因等事项
智通财经网·2025-09-12 12:58